Biosite Triage BNP Heart Failure Blood Test Has 84.4% Sensitivity
This article was originally published in The Gray Sheet
Executive Summary
Biosite Diagnostics' Triage B-Type Natriuretic Peptide (BNP) point-of-care test shows a sensitivity of 84.4% and a specificity of 95.6%, according to data supporting the firm's premarket approval application.
You may also be interested in...
Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing
Biosite expects to present data comparing its Triage Stroke Panel to computed axial tomography (CAT) to FDA's Clinical Chemistry & Toxicology Devices Panel this year
Biosite On Track To Earn First Rapid Stroke Assay Approval With PMA Filing
Biosite expects to present data comparing its Triage Stroke Panel to computed axial tomography (CAT) to FDA's Clinical Chemistry & Toxicology Devices Panel this year
Biosite Triage BNP Reduces Diagnosis Uncertainty To 11%, NEJM Study Finds
Biosite plans to file a 510(k) application in mid-2003 seeking a therapeutic monitoring indication for its Triage B-type natriuretic peptide (BNP) test to aid in diagnosis of congestive heart failure